Novo Nordisk CEO Mike Doustdar sought to reassure investors on Wednesday that the drugmaker can rebuild its pipeline, pledging faster research and bolt-on acquisitions after an upgraded 2026 outlook failed to lift sentiment. The Danish drugmaker raised its full-year profit and sales outlook late Tuesday but investors focused instead on slightly weaker-than-expected sales for its new Wegovy pill and another setback for next-generation obesity drug CagriSema, sending the shares down 4% in early trade.
Doustdar said Novo was evaluating several acquisition targets to complement its internal research but remained focused on smaller bolt-on deals rather than large acquisitions.
